Voting Rights and Shares Capital of the Company
NANOBIOTIX (Nasdaq: NBTX / Euronext: NANO) disclosed its voting rights and share capital data as of October 31, 2025. The company reports 48,237,471 shares outstanding, a theoretical total of 50,267,962 voting rights and 50,245,844 exercisable voting rights.
The notice follows French disclosure rules (AMF) and explains the difference between theoretical (gross) voting rights and exercisable (net) voting rights, excluding treasury shares. Contact details for communications and investor relations are provided.
NANOBIOTIX (Nasdaq: NBTX / Euronext: NANO) ha comunicato i dati sui diritti di voto e sul capitale sociale al 31 ottobre 2025. La société riporta 48.237.471 azioni in circolazione, un totale teorico di 50.267.962 diritti di voto e 50.245.844 diritti di voto esercitabili. L'avviso segue le norme di disclosure francesi (AMF) e spiega la differenza tra diritti di voto teorici (loro) e diritti di voto esercitabili (netti), escludendo le azioni in tesoreria. Sono forniti i dettagli di contatto per le comunicazioni e per le relazioni con gli investitori.
NANOBIOTIX (Nasdaq: NBTX / Euronext: NANO) divulgó sus datos sobre los derechos de voto y el capital social al 31 de octubre de 2025. la empresa reporta 48.237.471 acciones en circulación, un total teórico de 50.267.962 derechos de voto y 50.245.844 derechos de voto ejercitables. El aviso sigue las normas de divulgación francesas (AMF) y explica la diferencia entre derechos de voto teóricos (brutos) y derechos de voto ejercitables (netos), excluyendo las acciones en tesorería. Se proporcionan los datos de contacto para comunicaciones y relaciones con inversores.
NANOBIOTIX(Nasdaq: NBTX / Euronext: NANO) 은 2025년 10월 31일 현재 의결권 및 자본 데이터 를 공개했습니다. 회사는 유통 주식 48,237,471주, 이론적 총 의결권 50,267,962개, 행사 가능한 의결권 50,245,844개를 보고합니다. 공고는 프랑스의 공시 규칙(AMF)을 따르며 이론적(총액) 의결권과 행사 가능한(순액) 의결권의 차이를 설명하고 재무주식은 제외합니다. 커뮤니케이션 및 투자자 관계 관련 연락처가 제공됩니다.
NANOBIOTIX (Nasdaq : NBTX / Euronext : NANO) a dévoilé ses données sur les droits de vote et le capital social au 31 octobre 2025. La société indique 48 237 471 actions en circulation, un total théorique de 50 267 962 droits de vote et 50 245 844 droits de vote exerçables. L'avis respecte les règles de divulgation françaises (AMF) et explique la différence entre droits de vote théoriques (bruts) et droits de vote exerçables (nets), en excluant les actions propres. Des coordonnées pour les communications et les relations investisseurs sont fournies.
NANOBIOTIX (Nasdaq: NBTX / Euronext: NANO) hat ihre Daten zu Stimmrechten und Kapitalstand per 31. Oktober 2025 offengelegt. Das Unternehmen meldet 48.237.471 ausstehende Aktien, eine theoretische Gesamtzahl von 50.267.962 Stimmrechten und 50.245.844 ausübbaren Stimmrechten. Die Mitteilung folgt den französischen Offenlegungsregeln (AMF) und erläutert den Unterschied zwischen theoretischen (brutto) Stimmrechten und ausübbaren (netto) Stimmrechten, wobei Treasury-Aktien ausgeschlossen sind. Kontaktdaten für Mitteilungen und Investor Relations werden bereitgestellt.
نانوبيوتكس (ناسداك: NBTX / يورونكست: NANO) كشفت عن بيانات حقوق التصويت ورأس المال كما في 31 أكتوبر 2025. تُبلغ الشركة عن 48,237,471 سهماً قرضاً، وإجمالي افتراضي لحقوق التصويت يبلغ 50,267,962 وحقوق التصويت القابلة لممارسة تبلغ 50,245,844. الإخطار يتبع قواعد الإفصاح الفرنسية (AMF) ويشرح الفرق بين حقوق التصويت النظرية (الإجمالية) وحقوق التصويت القابلة للممارسة (الصافية)، مع استبعاد الأسهم المحفوظة. تُقدم تفاصيل الاتصال للاتصالات والعلاقات مع المستثمرين.
- None.
- None.
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Nov. 14, 2025 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
| Date | Number of Shares Outstanding | Total number of voting rights | |
| Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
| October 31, 2025 | 48,237,471 | 50,267,962 | 50,245,844 |
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
_________________
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.
Contacts
| Nanobiotix | |
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com |
| Media Relations | |
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com |
Attachment
- 2025-11-14 -- NBTX -- Voting Rights + Shares Capital -- FINAL
FAQ
What voting rights did NANOBIOTIX (NBTX) report on November 14, 2025?
How many shares outstanding did NANOBIOTIX (NBTX) disclose for October 31, 2025?
Why does NANOBIOTIX (NBTX) report two voting rights totals on November 14, 2025?
Where is NANOBIOTIX (NBTX) listed and which ISIN applies to the November 14, 2025 notice?
Who can investors contact about the NANOBIOTIX (NBTX) voting rights disclosure dated November 14, 2025?
